Replies to post #776871 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

Preparations are underway for number sequencings to attempt to plan for and fully engage with local Lottery retailers in seeking potential Powerball result opportunities.

[learningcurve2020]

Don't let AI and others lead you to beleive Flaskworks is only about DC's. The backup plan is for T's. Advent should do very well.  🤷🏼‍♀️
>>These cell culture systems and methods greatly reduce the number of manual steps compared to conventional protocols. In this way, the risks of contamination are greatly decreased and the robustness and reproducibility of the manufacturing technique are greatly increased, both key considerations for safe and reliable manufacturing of therapeutic products, such as personalized T cell therapies capable of precise targeting.

[JerryCampbell]

Your post said:

"From the 2025 10-K" for the first quote.

"From the Q1 2025 10-Q" for the second quote. That's why I suspected an AI fail since there is no 10-Q for Q1 as that is when the 10-K is issued.

Your most recent post is just trying to cover up for being caught in BLATANT LIES, fabricating SEC quotes.

[exwannabe]

So after admitting that neither of your original quotes existed you now are using a different quote from the 2022 10K and another nonexistent quote allegedly from the 2023 ASM.

Problem is, you are ignoring the quote from the most recent 10K

During 2024, the Company’s Flaskworks subsidiary and a specialized contractor developed a GMP-compatible prototype of the Flaskworks system for a “closed” manufacturing process for DCVax-L. Another prototype, with smaller dimensions, had been developed in 2023. The Company has determined that the smaller prototype will be preferable, to enable more units to fit in each manufacturing lab. Production of the GMP-grade units will be timed to coincide with the timing for buildout of Grade C labs in the Sawston facility. When the GMP-grade units are delivered, Advent BioServices will undertake qualification and validation of those units, conduct engineering runs and collect data, and apply to regulators for approval to use the system to produce DCVax-L for patients. As previously reported, the Company views the Flaskworks program and system as a centerpiece of efforts toward scale-up for potential commercial operations.

Crystal clear that they were waiting in the C cleanrooms and concurrent delivery of EDEN devices to start the validation process going. And as we know, they had not yet started building the C cleanrooms.

An assertion from early 2023 that they are working towards it does not change the FACT that as of a few months ago it was still in the future.